Abstract
Objective: We aimed to compare amyloid deposition at the lobar cerebral microbleed (CMB) sites of cerebral amyloid angiopathy (CAA), Alzheimer’s disease (AD), and cognitively normal healthy controls (NC) and to propose a novel diagnostic method for differentiating CAA patients from AD patients with integrated 11C-Pittsburgh compound B (PIB) positron emission tomography (PET)/magnetic resonance (MR) and assess its diagnostic value.Methods: Nine CAA, 15 AD patients, and 15 NC subjects were enrolled in this study. Each subject underwent an 11C-PIB brain PET/MR examination. Susceptibility weighted imaging was assessed to detect CMB locations, and standardized uptake value ratios (SUVRs) were measured at these sites. Cortical PIB distributions were quantitatively evaluated. Patients with CAA, AD, and NC subjects were compared with global and regional cortical SUVRs at CMB cites. The diagnostic accuracy of MRI, PIB-PET, and PET/MR in differentiating CAA and AD was evaluated.Results: Lobar CMBs were detected in all the CAA patients, eight of the 15 AD patients (53.3%), and four of the 15 NC subjects (26.7%), respectively. The PIB deposition at CMB sites was significantly higher in CAA patients compared with AD patients and NC subjects in terms of SUVR (1.72 ± 0.10 vs. 1.42 ± 0.16 and 1.17 ± 0.08; p < 0.0001). The PIB deposition was associated with CMB locations and was greatest in the occipital and temporal regions of CAA patients. The global cortical PIB deposition was significantly higher in CAA than in NC subjects (1.66 ± 0.06 vs. 1.21 ± 0.06; p < 0.0001) and significantly lower than in AD patients (1.66 ± 0.06 vs. 1.86 ± 0.17; p < 0.0001). In contrast, the occipital/global PIB uptake ratio was significantly increased in CAA (occipital/global ratio, 1.05 ± 0.02) relative to AD patients (1.05 ± 0.02 vs. 0.99 ± 0.04; p < 0.001). PET/MR had a higher accuracy (sensitivity, 88.9%; specificity, 93.3%) than separate PET and MR.Conclusion: Our results indicate that the CMBs occur preferentially at loci with concentrated amyloid. By combining lobar CMBs with regional cortical amyloid deposition, the proposed workflow can further improve CAA diagnostic accuracy compared to each method alone. These findings improve our knowledge regarding the pathogenesis of CMBs and highlight the potential utility of PIB-PET/MR as a non-invasive tool for distinguishing CAA and AD patients.
Highlights
Cerebral amyloid angiopathy (CAA) is an extremely common small vessel disease (SVD) of the brain in elderly individuals
The clinical diagnosis of possible or probable CAA is currently based on the Boston criteria, which have been validated against the pathologic gold standard
These results are derived from a limited number of CAA patients, they could still provide insights into the mechanism by which vascular amyloid leads to cerebral microbleeds (CMBs)
Summary
Cerebral amyloid angiopathy (CAA) is an extremely common small vessel disease (SVD) of the brain in elderly individuals. It is caused by progressive amyloid-β protein accumulation within cerebral vessels, involving the cortical and leptomeningeal vessel walls (Vinters, 1987; Viswanathan and Greenberg, 2011; Charidimou et al, 2012). CAA is an important common cause of spontaneous lobar intracerebral hemorrhage (ICH), having a high risk of morbidity and mortality (Charidimou et al, 2012). Patients with more than two strictly, lobar ICH/cerebral microbleeds (CMBs) without an identified cause were diagnosed as “probable CAA”; these represent late and irreversible brain injuries. Patients with only one ICH or CMB are interpreted as “possible CAA.”. Patients with only one ICH or CMB are interpreted as “possible CAA.” For these patients, a diagnosis of early-stage CAA would change the medical management and reduce the risk of new ICHs (Shoamanesh et al, 2017)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.